Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Summary

This trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care, in patients who underwent curative resection of colorectal cancer and then tested positive for ctDNA.

Timeline

Start

2020-07-08

Primary completion

2024-07-18

Completion

2024-07-18

Publications

• Bando H, Watanabe J, Takahashi Y, Kotaka M, Matsuhashi N, Oki E, Komatsu Y, Shiozawa M, Hirata K, Miyamoto Y, Takahashi M, Yamazaki K, Manaka D, Kanazawa A, Liang YH, Yeh KH, Watsuji Y, Yamamoto Y, Fukui M, Sharma S, Aushev VN, Jurdi A, Rabinowitz M, Liu MC, Aleshin A, Takemasa I, Kotani D, Sato A, Misumi T, Nakamura Y, Shi Q, Taniguchi H, Yoshino T, Kato T. Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial. Nat Med. 2026 Jun 8. doi: 10.1038/s41591-026-04428-0. Online ahead of print.

Drugs

Indications